Validation of a dosing regimen for fixed-dose, weight-adjusted, subcutaneous unfractionated heparin for the acute treatment of venous thrombo-embolism in a population from a resource-constrained environment

To the Editor: A study in Canada and New Zealand (Kearon et al.) suggested that fixed-dose unmonitored subcutaneous (SC) unfractionated heparin (UFH) is as effective and safe as low-molecular-weight heparin (LMWH) for the acute treatment of venous thrombo-embolism (VTE). While this trial has limitations, it provides evidence to support the use of SC UFH in a resource-constrained environment. However, because public sector patients with VTE in South Africa often have multiple co-morbidities and are thinner and younger than those in that study, the local validity of the published dosing regimen is unclear.

Background

VTE is a potentially fatal disorder manifesting as deep-vein thrombosis (DVT) and pulmonary embolism (PE). Initial standard management of VTE was with intravenous UFH with dose adjustments according to the partial thromboplastin time (PTT). This regimen is effective, but is limited by the requirements for intensive monitoring and ensuring a constant heparin infusion rate. The introduction of SC LMWH using weight-based dosing offered an attractive alternative to UFH, with proven efficacy and safety. Although LMWH is more expensive, this cost is offset by reduced laboratory costs, as PTT monitoring is not required.

Kearon et al. performed a randomised, open-label, adjudicator-blinded trial (FIDO) suggesting that fixed-dose, weight-adjusted SC UFH, without PTT monitoring, appeared as effective and safe as fixed-dosed, unmonitored SC LMWH in patients with acute VTE. SC UFH was given as a loading dose of 333 units/kg followed by 250 units/kg 12-hourly. A recent review concluded that SC UFH appeared to be as effective and safe with regard to rates of bleeding and death. However, the authors declared that more robust data were needed to recommend SC UFH without PTT monitoring.

Although the use of LMWH is established, the considerably less costly approach of fixed-dose, weight-adjusted, SC UFH is appealing in a resource-constrained setting. However, there appears to be no published evidence to indicate that this regimen has been validated locally in patients who differ from those in the FIDO study in age, weight, and presence of multiple co-morbidities.

Methods

The protocol was approved by the East London Hospital Complex Research and Ethics Committee. The sample size was based on a previous study that looked at optimal dosing of SC UFH for the treatment of DVT. Patients provided written informed consent. Concurrent chart review was performed on all consecutive eligible patients (age ≥18 years; newly diagnosed VTE) admitted between November 2008 and February 2009 to internal medicine wards at Cecilia Makiwane Hospital and who had been prescribed SC UFH according to the FIDO study. All other aspects of care were delivered as standard of care. The primary measure of interest was the proportion of patients with a therapeutic PTT (patient PTT 1.5 - 2.5 times the control value) measured approximately 6 hours after the morning dose of UFH on any day from the 2nd to the 6th day of SC UFH therapy as in the FIDO regimen. Neither safety nor efficacy of patient outcomes were collected as the sample size was chosen only to validate the published dosing regimen.

Results

A total of 25 inpatients were recruited of whom 24 had acute DVT confirmed on Doppler ultrasound, and one had clinical evidence of PE and a strongly positive d-dimer result. The mean age of the patients was 37.6 years (SD 15.03); mean body weight 57.2 kg (SD 16.79) and 68% were female (Table I). Pulmonary tuberculosis was the most prevalent concomitant disease (64%). The mean loading and maintenance doses of UFH were 320 units/kg (SD 66.87) and 250 units/kg (SD 5.57) respectively. PTT was measured on a single blood sample obtained a mean of 6.0 hours (SD 0.37) after the morning dose and a mean of 3.48 days (SD 0.92) after starting SC UFH. Twelve (48%) of the 25 patients had a PTT within the therapeutic range, 8 (32%) patients were found to have a supratherapeutic PTT (patient value >2.5 times control value) and 5 (20%) had a sub-therapeutic PTT (patient value <1.5 times control value). The mean PTT ratio (PTT patient/PTT control) was 2.44 (SD 1.40; 95% CI 1.89 to 2.99). The mean duration of heparin therapy was 8.5 days (SD 3.39).

Discussion

Baseline characteristics of patients in this study including gender, age and weight differed from the SC UFH treatment arm in FIDO (Table I). There were relatively more women than...
men (68% versus 49% in FIDO) and the mean ages and weights were less (38 years v. 60 years and 57 kg v. 82 kg).

None of our patients had previous VTE, compared with 11% of patients in the SC UFH group in FIDO. Sixteen patients were diagnosed with DVT and concomitant tuberculosis but none in the SC UFH group in FIDO.

In FIDO, the PTT (therapeutic PTT: 60 - 85 seconds) was measured in 197 patients, a mean of 6.0 hours after the morning dose and a mean of 2.8 days after starting UFH. Thirty-seven patients (19%) had a PTT within the therapeutic range, 121 (61%) were found to be supratherapeutic (>85 seconds) and 39 (20%) sub-therapeutic (<60 seconds). A higher proportion of patients in our cohort appeared to have therapeutic values, while a lower proportion had supratherapeutic and a similar proportion sub-therapeutic values. The low sub-therapeutic ratio for 1 patient in our cohort may be attributed to 2 dose omissions prior to the blood samples taken for PTT monitoring.

**Conclusion**

In a small but real-world pragmatic study, the use of a weight-based dosing nomogram appeared feasible, and PTT results obtained were within the range achieved in a previous large trial comparing LMWH with fixed-dose, weight-based SC UFH. Our study provides preliminary support for the local generalisability of the FIDO dosing model, offering a promising alternative for the treatment of VTE in a resource-constrained environment.

**Table I. Comparison between this study, FIDO and the dose validation study**

<table>
<thead>
<tr>
<th></th>
<th>This study</th>
<th>Dose validation</th>
<th>FIDO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients</td>
<td>25</td>
<td>20</td>
<td>355</td>
</tr>
<tr>
<td>Age, mean (SD) years</td>
<td>38 (15)</td>
<td>67</td>
<td>60 (17)</td>
</tr>
<tr>
<td>Weight, mean (SD) kg</td>
<td>57 (17)</td>
<td>78</td>
<td>82 (19)</td>
</tr>
<tr>
<td>Women (%)</td>
<td>68</td>
<td>60</td>
<td>49</td>
</tr>
<tr>
<td><strong>PTT (Day 3)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapeutic, No. (%)</td>
<td>12 (48)</td>
<td>4 (20)</td>
<td>37 (19)</td>
</tr>
<tr>
<td>Supratherapeutic, No. (%)</td>
<td>8 (32)</td>
<td>12 (60)</td>
<td>121 (61)</td>
</tr>
<tr>
<td>Sub-therapeutic, No. (%)</td>
<td>5 (20)</td>
<td>4 (20)</td>
<td>39 (20)</td>
</tr>
</tbody>
</table>

Note: PTT was measured in 197 patients in the unfractionated heparin arm of FIDO.

**References**


**Accepted 11 May 2010.**